Sareum Holdings – Key ‘737 data coming up

Sareum’s investment case stands on two pillars: the development by licensee Sierra Oncology of the Chk1 inhibitor, SRA737; and the development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer.... Read more This year should see the first clinical data on SRA737, as well as further data ...

Page 4233 of 6210 1 4,232 4,233 4,234 6,210
-->